Back to Search
Start Over
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF.
- Source :
-
The Journal of clinical investigation [J Clin Invest] 2002 Mar; Vol. 109 (6), pp. 805-15. - Publication Year :
- 2002
-
Abstract
- Acute intensive insulin therapy is an independent risk factor for diabetic retinopathy. Here we demonstrate that acute intensive insulin therapy markedly increases VEGF mRNA and protein levels in the retinae of diabetic rats. Retinal nuclear extracts from insulin-treated rats contain higher hypoxia-inducible factor-1alpha (HIF-1alpha) levels and demonstrate increased HIF-1alpha-dependent binding to hypoxia-responsive elements in the VEGF promoter. Blood-retinal barrier breakdown is markedly increased with acute intensive insulin therapy but can be reversed by treating animals with a fusion protein containing a soluble form of the VEGF receptor Flt; a control fusion protein has no such protective effect. The insulin-induced retinal HIF-1alpha and VEGF increases and the related blood-retinal barrier breakdown are suppressed by inhibitors of p38 mitogen-activated protein kinase (MAPK) and phosphatidylinositol (PI) 3-kinase, but not inhibitors of p42/p44 MAPK or protein kinase C. Taken together, these findings indicate that acute intensive insulin therapy produces a transient worsening of diabetic blood-retinal barrier breakdown via an HIF-1alpha-mediated increase in retinal VEGF expression. Insulin-induced VEGF expression requires p38 MAPK and PI 3-kinase, whereas hyperglycemia-induced VEGF expression is HIF-1alpha-independent and requires PKC and p42/p44 MAPK. To our knowledge, these data are the first to identify a specific mechanism for the transient worsening of diabetic retinopathy, specifically blood-retinal barrier breakdown, that follows the institution of intensive insulin therapy.
- Subjects :
- Animals
Blood-Retinal Barrier physiology
Cell Nucleus metabolism
Cells, Cultured
Culture Media, Conditioned
Diabetic Retinopathy physiopathology
Disease Models, Animal
Drug Implants
Endothelial Growth Factors genetics
Glucose metabolism
Glucose pharmacology
Humans
Hypoxia-Inducible Factor 1
Hypoxia-Inducible Factor 1, alpha Subunit
Insulin therapeutic use
Lymphokines genetics
Male
Mitogen-Activated Protein Kinases antagonists & inhibitors
Mitogen-Activated Protein Kinases metabolism
Phosphatidylinositol 3-Kinases metabolism
Phosphoinositide-3 Kinase Inhibitors
Proto-Oncogene Proteins genetics
Proto-Oncogene Proteins metabolism
Rats
Rats, Long-Evans
Receptor Protein-Tyrosine Kinases genetics
Receptor Protein-Tyrosine Kinases metabolism
Recombinant Fusion Proteins metabolism
Retina cytology
Transcription Factors metabolism
Transcriptional Activation physiology
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factors
Blood-Retinal Barrier drug effects
DNA-Binding Proteins metabolism
Diabetes Mellitus physiopathology
Endothelial Growth Factors metabolism
Insulin pharmacology
Lymphokines metabolism
Nuclear Proteins metabolism
Retina metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 0021-9738
- Volume :
- 109
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- The Journal of clinical investigation
- Publication Type :
- Academic Journal
- Accession number :
- 11901189
- Full Text :
- https://doi.org/10.1172/JCI13776